NASDAQ:OREX - Orexigen Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2229 -0.12 (-35.00 %)
(As of 05/27/2018 05:51 AM ET)
Previous Close$0.2229
Today's Range$0.22 - $0.3198
52-Week Range$0.17 - $3.81
Volume3.74 million shs
Average Volume1.16 million shs
Market Capitalization$4.21 million
P/E Ratio-0.03
Dividend YieldN/A
Beta2.46

About Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics logoOrexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Receive OREX News and Ratings via Email

Sign-up to receive the latest news and ratings for OREX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:OREX
CUSIP68616410
Phone858-875-8600

Debt

Debt-to-Equity Ratio-2.75
Current Ratio2.00
Quick Ratio1.71

Price-To-Earnings

Trailing P/E Ratio-0.03
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.71 million
Price / Sales0.12
Cash FlowN/A
Price / CashN/A
Book Value$3.91 per share
Price / Book0.06

Profitability

EPS (Most Recent Fiscal Year)($6.92)
Net Income$-24,520,000.00
Net Margins-192.65%
Return on EquityN/A
Return on Assets-68.53%

Miscellaneous

Employees132
Outstanding Shares18,890,000

Orexigen Therapeutics (NASDAQ:OREX) Frequently Asked Questions

What is Orexigen Therapeutics' stock symbol?

Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."

How were Orexigen Therapeutics' earnings last quarter?

Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued its quarterly earnings data on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($2.13) by $0.78. The biopharmaceutical company earned $18.90 million during the quarter, compared to analyst estimates of $24.20 million. The business's quarterly revenue was up 170.0% compared to the same quarter last year. During the same period last year, the firm earned $1.12 EPS. View Orexigen Therapeutics' Earnings History.

Who are some of Orexigen Therapeutics' key competitors?

Who are Orexigen Therapeutics' key executives?

Orexigen Therapeutics' management team includes the folowing people:
  • Mr. Michael A. Narachi, Pres, Chief Exec. Officer & Director (Age 59)
  • Dr. Thomas R. Cannell D.V.M., Exec. VP, COO & Pres of Global Commercial Products (Age 56)
  • Mr. Thomas P. Lynch, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 51)
  • Ms. Monica Forbes, VP & Acting CFO (Age 42)
  • Mr. Stephen A. Moglia, Chief Accounting Officer, VP and Controller (Age 53)

Has Orexigen Therapeutics been receiving favorable news coverage?

Press coverage about OREX stock has trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Orexigen Therapeutics earned a news sentiment score of 0.14 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.43 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Orexigen Therapeutics' major shareholders?

Orexigen Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BVF Inc. IL (2.83%). View Institutional Ownership Trends for Orexigen Therapeutics.

Which major investors are selling Orexigen Therapeutics stock?

OREX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL. View Insider Buying and Selling for Orexigen Therapeutics.

How do I buy shares of Orexigen Therapeutics?

Shares of OREX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Orexigen Therapeutics' stock price today?

One share of OREX stock can currently be purchased for approximately $0.2229.

How big of a company is Orexigen Therapeutics?

Orexigen Therapeutics has a market capitalization of $4.21 million and generates $33.71 million in revenue each year. The biopharmaceutical company earns $-24,520,000.00 in net income (profit) each year or ($6.92) on an earnings per share basis. Orexigen Therapeutics employs 132 workers across the globe.

How can I contact Orexigen Therapeutics?

Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-875-8600 or via email at [email protected]


MarketBeat Community Rating for Orexigen Therapeutics (OREX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  409
MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe OREX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OREX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Orexigen Therapeutics (NASDAQ:OREX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Orexigen Therapeutics in the last 12 months. There are currently 1 sell rating for the stock, resulting in a consensus rating of "Sell."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: SellSellN/AN/A
Consensus Rating Score: 1.001.00N/AN/A
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Orexigen Therapeutics (NASDAQ:OREX) Consensus Price Target History

Price Target History for Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics (NASDAQ:OREX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2018Wells Fargo & CoDowngradeUnderperformHighView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Orexigen Therapeutics (NASDAQ:OREX) Earnings History and Estimates Chart

Earnings by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics (NASDAQ OREX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($2.13)($1.35)$24.20 million$18.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($2.40)($1.82)$20.00 million$23.36 millionViewListenView Earnings Details
5/9/2017Q1 2017($2.60)($4.67)$20.00 million$19.10 millionViewListenView Earnings Details
3/28/2017Q4 2016($0.54)($2.67)$13.88 millionViewN/AView Earnings Details
11/3/2016Q316($2.24)$1.12$8.17 million$7.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.47)($1.73)$6.88 million$7.79 millionViewListenView Earnings Details
5/4/2016Q116($0.17)($0.15)$7.78 million$5.00 millionViewListenView Earnings Details
2/26/2016Q415($0.08)($0.12)$14.07 million$4.90 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.09)$12.17 million$10.00 millionViewListenView Earnings Details
8/6/2015Q215($0.17)($0.18)$4.92 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115($0.16)($0.14)$7.28 million$4.36 millionViewListenView Earnings Details
11/10/2014Q3($0.13)$0.09$8.93 million$30.90 millionViewListenView Earnings Details
8/7/2014Q2($0.21)($0.21)$51.80 million$0.86 millionViewListenView Earnings Details
5/8/2014Q1($0.20)($0.23)$0.93 million$0.86 millionViewListenView Earnings Details
3/12/2014Q4($0.19)($0.21)$900.00 million$857.00 millionViewListenView Earnings Details
11/12/2013Q3($0.18)($0.19)$0.80 million$0.8570 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.19)($0.19)$0.90 million$0.86 millionViewListenView Earnings Details
5/8/2013Q1 2013($3.40)($2.10)$0.92 million$0.86 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.44)($0.41)$0.91 million$0.8570 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.44)ViewN/AView Earnings Details
8/7/2012Q2 2012($1.70)($2.46)ViewN/AView Earnings Details
5/9/2012Q1 2012($1.20)($1.58)ViewN/AView Earnings Details
3/8/2012Q4 2011($1.00)($0.88)ViewN/AView Earnings Details
11/8/2011Q3 2011($1.40)($0.95)ViewN/AView Earnings Details
8/8/2011Q2 2011($2.00)($1.60)ViewN/AView Earnings Details
5/9/2011Q1 2011($2.10)($2.42)ViewN/AView Earnings Details
3/10/2011Q4 2010($2.90)($2.37)ViewN/AView Earnings Details
11/3/2010Q3 2010($2.70)($3.09)ViewN/AView Earnings Details
8/5/2010Q2 2010($3.20)($2.52)ViewN/AView Earnings Details
5/10/2010Q1 2010($3.00)($2.98)ViewN/AView Earnings Details
3/9/2010Q4 2009($2.80)($3.19)ViewN/AView Earnings Details
11/4/2009Q3 2009($3.60)($3.30)ViewN/AView Earnings Details
8/6/2009Q2 2009($5.60)($5.14)ViewN/AView Earnings Details
5/7/2009Q1 2009($5.80)($5.58)ViewN/AView Earnings Details
3/12/2009Q4 2008($7.20)($6.43)ViewN/AView Earnings Details
11/6/2008Q3 2008($6.50)($7.21)ViewN/AView Earnings Details
8/7/2008Q2 2008($6.60)($6.74)ViewN/AView Earnings Details
5/8/2008Q1 2008($6.10)($7.27)ViewN/AView Earnings Details
3/13/2008Q4 2007($6.70)($7.21)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Orexigen Therapeutics (NASDAQ:OREX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Orexigen Therapeutics (NASDAQ OREX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 36.43%
Insider Trading History for Orexigen Therapeutics (NASDAQ:OREX)
Institutional Ownership by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics (NASDAQ OREX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Stephen A MogliaVPSell1,694$0.24$406.56View SEC Filing  
12/19/2016Stephen A. MogliaVPSell800$1.96$1,568.00View SEC Filing  
12/2/2014Heather D TurnerSVPSell22,643$6.00$135,858.00View SEC Filing  
11/25/2014Heather D TurnerSVPSell31,388$5.83$182,992.04View SEC Filing  
11/18/2014Louis C BockDirectorBuy1,325$5.58$7,393.50View SEC Filing  
11/12/2014Louis C BockDirectorBuy27,052$5.57$150,679.64View SEC Filing  
9/22/2014Heather D TurnerVPSell300,000$4.47$1,341,000.00View SEC Filing  
9/15/2014Joseph P HaganVPBuy5,000$4.69$23,450.00View SEC Filing  
9/15/2014Michael NarachiCEOBuy50,000$4.78$239,000.00View SEC Filing  
7/31/2013Joseph P HaganInsiderSell12,000$7.80$93,600.00View SEC Filing  
7/26/2013Joseph P HaganInsiderSell10,000$7.40$74,000.00View SEC Filing  
7/25/2013Preston KlassenSVPSell71,229$7.16$509,999.64View SEC Filing  
5/28/2013Joseph P HaganInsiderSell28,000$7.00$196,000.00View SEC Filing  
5/28/2013Preston KlassenSVPSell28,771$7.21$207,438.91View SEC Filing  
1/15/2013Mark D BoothInsiderSell22,315$6.67$148,841.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Orexigen Therapeutics (NASDAQ OREX) News Headlines

Source:
DateHeadline
Orexigen agrees to sell itself to Nalpropion Pharma for $75M; shares down 34%Orexigen agrees to sell itself to Nalpropion Pharma for $75M; shares down 34%
seekingalpha.com - April 25 at 10:27 AM
Orexigen Therapeutics (OREX) Reports Agreement for Sale of CompanyOrexigen Therapeutics (OREX) Reports Agreement for Sale of Company
www.streetinsider.com - April 24 at 9:55 AM
[$$] Pernix, Investor Group Offer $75 Million for Orexigen[$$] Pernix, Investor Group Offer $75 Million for Orexigen
finance.yahoo.com - April 24 at 9:55 AM
BRIEF-Pernix Therapeutics Announces Participation In Lead Bid Worldwide Rights Of ContraveBRIEF-Pernix Therapeutics Announces Participation In Lead Bid Worldwide Rights Of Contrave
www.reuters.com - April 23 at 4:01 PM
BRIEF-Orexigen Therapeutics Enters Agreement For Sale Of CoBRIEF-Orexigen Therapeutics Enters Agreement For Sale Of Co
www.reuters.com - April 23 at 4:01 PM
Orexigen Therapeutics, Inc. Enters Agreement for Sale of CompanyOrexigen Therapeutics, Inc. Enters Agreement for Sale of Company
finance.yahoo.com - April 23 at 4:01 PM
Orexigen Therapeutics (OREX) Stock Rating Upgraded by ValuEngineOrexigen Therapeutics (OREX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 19 at 2:24 PM
[$$] Orexigen Incentive, Retention Plans Opposed by Unsecured Creditors[$$] Orexigen Incentive, Retention Plans Opposed by Unsecured Creditors
finance.yahoo.com - April 11 at 4:07 PM
Orexigen Therapeutics, Inc. (OREX) Short Interest Down 34.7% in MarchOrexigen Therapeutics, Inc. (OREX) Short Interest Down 34.7% in March
www.americanbankingnews.com - March 31 at 1:45 AM
[$$] Firm Retention Summary: Orexigen Therapeutics Inc.[$$] Firm Retention Summary: Orexigen Therapeutics Inc.
finance.yahoo.com - March 28 at 10:00 AM
Should You Buy Orexigen Therapeutics Inc (NASDAQ:OREX) At $0.22?Should You Buy Orexigen Therapeutics Inc (NASDAQ:OREX) At $0.22?
finance.yahoo.com - March 23 at 9:30 AM
30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets
finance.yahoo.com - March 22 at 4:22 PM
Orexigen Files For Bankruptcy - Investors Need To Get Savvy - Seeking AlphaOrexigen Files For Bankruptcy - Investors Need To Get Savvy - Seeking Alpha
seekingalpha.com - March 19 at 4:14 PM
Orexigen Therapeutics (OREX) Downgraded by Wells Fargo to UnderperformOrexigen Therapeutics (OREX) Downgraded by Wells Fargo to Underperform
www.americanbankingnews.com - March 18 at 11:25 AM
Orexigen Plummets on Filing of Chapter 11 of Bankruptcy CodeOrexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
finance.yahoo.com - March 14 at 12:40 PM
[$$] Orexigen to Use Some Bankruptcy Financing on Advertising[$$] Orexigen to Use Some Bankruptcy Financing on Advertising
finance.yahoo.com - March 14 at 12:40 PM
Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for BankruptcyBiotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy
finance.yahoo.com - March 14 at 12:40 PM
Orexigen, Advaxis Tumble into Tuesdays 52-Week Low Club - 24/7 Wall St.Orexigen, Advaxis Tumble into Tuesday's 52-Week Low Club - 24/7 Wall St.
247wallst.com - March 13 at 4:22 PM
Obesity drug developer Orexigen in bankruptcy to pursue sale - ReutersObesity drug developer Orexigen in bankruptcy to pursue sale - Reuters
www.reuters.com - March 13 at 4:22 PM
Orexigen Therapeutics (OREX) to File Chapter 11 BankruptcyOrexigen Therapeutics (OREX) to File Chapter 11 Bankruptcy
www.streetinsider.com - March 13 at 11:35 AM
US STOCKS-Wall Street set to open higher as inflation worries easeUS STOCKS-Wall Street set to open higher as inflation worries ease
finance.yahoo.com - March 13 at 11:35 AM
Orexigen Bankruptcy Shows Difficulty of Marketing Weight-Loss DrugsOrexigen Bankruptcy Shows Difficulty of Marketing Weight-Loss Drugs
finance.yahoo.com - March 13 at 11:35 AM
Mid-Day Market Update: Dow Turns Negative; United Community Bancorp Shares Spike Higher - NasdaqMid-Day Market Update: Dow Turns Negative; United Community Bancorp Shares Spike Higher - Nasdaq
www.nasdaq.com - March 12 at 4:03 PM
Mid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge - NasdaqMid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge - Nasdaq
www.nasdaq.com - March 12 at 4:03 PM
BRIEF-Orexigen Therapeutics says plans near-term sale through Chapter 11 of US bankruptcy code - ReutersBRIEF-Orexigen Therapeutics says plans near-term sale through Chapter 11 of US bankruptcy code - Reuters
www.reuters.com - March 12 at 5:19 AM
[$$] Orexigen Plans to Sell Itself Through Chapter 11 Bankruptcy[$$] Orexigen Plans to Sell Itself Through Chapter 11 Bankruptcy
finance.yahoo.com - March 12 at 5:19 AM
Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy CodeOrexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code
www.prnewswire.com - March 12 at 2:26 AM
Orexigen Therapeutics, Inc. (OREX) Expected to Post Earnings of -$2.06 Per ShareOrexigen Therapeutics, Inc. (OREX) Expected to Post Earnings of -$2.06 Per Share
www.americanbankingnews.com - March 4 at 1:32 PM
Sangamo Therapeutics Announces Appointment Of Heather D. Turner As Senior Vice President And General Counsel - PR Newswire (press release)Sangamo Therapeutics Announces Appointment Of Heather D. Turner As Senior Vice President And General Counsel - PR Newswire (press release)
www.prnewswire.com - February 13 at 6:13 AM
Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its ... - Business Wire (press release)Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its ... - Business Wire (press release)
www.businesswire.com - February 9 at 3:27 PM
Orexigen Therapeutics (OREX) Lifted to "Sell" at ValuEngineOrexigen Therapeutics (OREX) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 6:36 PM
Global Anti-Obesity Drugs Market 2017-2023: Market is Estimated to Witness a CAGR of 20.9% - Key Players are F. Hoffmann La Roche, GSK, Orexigen Therapeutics, Vivus Therapeutics, and EisaiGlobal Anti-Obesity Drugs Market 2017-2023: Market is Estimated to Witness a CAGR of 20.9% - Key Players are F. Hoffmann La Roche, GSK, Orexigen Therapeutics, Vivus Therapeutics, and Eisai
www.prnewswire.com - February 1 at 8:06 AM
-$2.06 Earnings Per Share Expected for Orexigen Therapeutics, Inc. (OREX) This Quarter-$2.06 Earnings Per Share Expected for Orexigen Therapeutics, Inc. (OREX) This Quarter
www.americanbankingnews.com - January 29 at 9:14 PM
Why Orexigen Therapeutics Inc’s (NASDAQ:OREX) Ownership Structure Is ImportantWhy Orexigen Therapeutics Inc’s (NASDAQ:OREX) Ownership Structure Is Important
finance.yahoo.com - January 24 at 8:50 AM
BRIEF-Orexigen Therapeutics Says ‍Expect Annualized Savings Associated With Feb 2018 Reduction In Sales Force Of About $30 MlnBRIEF-Orexigen Therapeutics Says ‍Expect Annualized Savings Associated With Feb 2018 Reduction In Sales Force Of About $30 Mln
www.reuters.com - January 19 at 11:45 AM
Orexigen Therapeutics (OREX) Upgraded by Zacks Investment Research to HoldOrexigen Therapeutics (OREX) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 16 at 11:54 AM
Orexigen Struggles as Contrave Commercialization Costs RiseOrexigen Struggles as Contrave Commercialization Costs Rise
www.zacks.com - January 4 at 4:38 PM
Orexigen Therapeutics (OREX) Downgraded by Zacks Investment Research to SellOrexigen Therapeutics (OREX) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - January 4 at 6:04 AM
ETFs with exposure to Orexigen Therapeutics, Inc. : December 27, 2017ETFs with exposure to Orexigen Therapeutics, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 1:54 PM
Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 27 at 1:54 PM
Zacks: Brokerages Expect Orexigen Therapeutics, Inc. (OREX) Will Announce Earnings of -$2.06 Per ShareZacks: Brokerages Expect Orexigen Therapeutics, Inc. (OREX) Will Announce Earnings of -$2.06 Per Share
www.americanbankingnews.com - December 27 at 12:33 PM
Comparing Orexigen Therapeutics (OREX) and MacroGenics (MGNX)Comparing Orexigen Therapeutics (OREX) and MacroGenics (MGNX)
www.americanbankingnews.com - December 11 at 9:52 PM
Implied Volatility Surging for Orexigen (OREX) Stock OptionsImplied Volatility Surging for Orexigen (OREX) Stock Options
finance.yahoo.com - December 8 at 10:16 AM
Is Orexigen Therapeutics Inc (OREX) An Industry Laggard Or Leader?Is Orexigen Therapeutics Inc (OREX) An Industry Laggard Or Leader?
finance.yahoo.com - December 1 at 5:35 PM
Ophthotech (OPHT) vs. Orexigen Therapeutics (OREX) Head to Head AnalysisOphthotech (OPHT) vs. Orexigen Therapeutics (OREX) Head to Head Analysis
www.americanbankingnews.com - November 28 at 5:38 AM
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt ... - PR Newswire (press release)Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt ... - PR Newswire (press release)
www.prnewswire.com - November 15 at 7:11 AM
Earnings Reaction History: Orexigen Therapeutics, Inc., 62.5% Follow-Through Indicator, 7.7% Sensitive - NasdaqEarnings Reaction History: Orexigen Therapeutics, Inc., 62.5% Follow-Through Indicator, 7.7% Sensitive - Nasdaq
www.nasdaq.com - November 15 at 7:11 AM
Orexigen Therapeutics Announces Third Quarter 2017 Financial ... - PR Newswire (press release)Orexigen Therapeutics Announces Third Quarter 2017 Financial ... - PR Newswire (press release)
www.prnewswire.com - November 15 at 7:11 AM
What Does Orexigen Therapeutics Inc’s (OREX) Share Price Indicate?What Does Orexigen Therapeutics Inc’s (OREX) Share Price Indicate?
finance.yahoo.com - November 15 at 7:11 AM
Orexigen Therapeutics, Inc. (OREX) Announces Quarterly  Earnings Results, Beats Expectations By $0.78 EPSOrexigen Therapeutics, Inc. (OREX) Announces Quarterly Earnings Results, Beats Expectations By $0.78 EPS
www.americanbankingnews.com - November 14 at 10:30 AM

SEC Filings

Orexigen Therapeutics (NASDAQ:OREX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Orexigen Therapeutics (NASDAQ:OREX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Orexigen Therapeutics (NASDAQ OREX) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.